Intensive blood-pressure control did not cut dementia risk in a diabetes trial
BPROAD randomised 12,434 adults with type 2 diabetes to a systolic target under 120 or under 140 mm Hg. After nearly four years, dementia or mild cognitive impairment was no less common with the tighter target.
| Group | Value (events per 100 person-years) |
|---|---|
| Intensive (under 120 mm Hg) | 3.69 |
| Standard (under 140 mm Hg) | 3.89 |
Lowering blood pressure aggressively protects the heart and the kidneys. Whether it also protects the brain has been one of the open questions in cardiovascular medicine. A large Chinese trial has now tested that idea directly in adults with type 2 diabetes, and the answer is sobering: pushing systolic blood pressure well below the usual target did not reduce the incidence of dementia or mild cognitive impairment over nearly four years [s1].
The analysis is a prespecified look at the secondary cognitive outcomes of BPROAD, the Blood Pressure Control Target in Diabetes trial, registered as NCT03808311 [s1][s2].
What the trial did
BPROAD was a multicentre, open-label, outcome-assessor-masked randomised controlled trial run at 145 clinical centres across seven geographical regions in China [s1]. It enrolled 12,821 adults aged 50 or older who had type 2 diabetes, raised systolic blood pressure and increased cardiovascular risk. For this cognitive ancillary study, the 12,434 participants who did not have probable dementia at baseline were followed, with cognitive assessments repeated annually and at the end of the study [s1].
Participants were randomly assigned to one of two strategies for up to five years: intensive treatment targeting a systolic pressure below 120 mm Hg, or standard treatment targeting below 140 mm Hg [s1]. In total, 6,219 were assigned to the intensive group and 6,215 to the standard group. Their mean age at baseline was 63.7 years, and 5,567 (44.8%) were women [s1].
The targets translated into a real separation in achieved pressure. After one year, mean systolic blood pressure was 121.6 mm Hg in the intensive group against 133.2 mm Hg in the standard group — a gap of roughly 12 mm Hg that the trial sustained [s1]. The primary cognitive outcome was a composite of all-cause dementia or mild cognitive impairment. A subset of participants also underwent brain magnetic resonance imaging at baseline (862 people) and at the end of the study (605 people) to measure changes in white-matter lesion volume and total brain volume [s1].
What it found
Over a median follow-up of 3.8 years, the composite of dementia or mild cognitive impairment occurred in 747 participants in the intensive group — 3.69 events per 100 person-years — and in 783 participants in the standard group, 3.89 events per 100 person-years [s1]. The hazard ratio was 0.96, with a 95% confidence interval from 0.86 to 1.06 and a P value of 0.38 [s1]. That is a result sitting almost exactly on no effect, with an interval that rules out any large cognitive benefit from the tighter target.
The brain-imaging substudy told a slightly more interesting story. Among the participants scanned (428 in the intensive group versus 434 in the standard group), the intensive group accumulated less white-matter lesion volume: a between-group difference of −0.09 on an inverse hyperbolic sine-transformed scale of cubic centimetres, with a 95% confidence interval from −0.15 to −0.02 and a P value of 0.01 [s1]. White-matter lesions are a marker of small-vessel damage in the brain, so slowing their accrual is biologically plausible for lower blood pressure — but it is a change on an imaging measure, not a change in whether people developed dementia.
How to read it
This is a null result on the outcome that matters most to patients, delivered by a trial built to detect a difference if one existed. BPROAD randomised more than 12,000 people, achieved a wide and durable separation in blood pressure between the groups, masked the assessors who judged cognitive outcomes, and followed participants for years [s1]. Those are the features that make a flat finding trustworthy rather than a sign the intervention was never given a fair test.
The honest summary is that, in adults with type 2 diabetes, driving systolic pressure below 120 mm Hg rather than below 140 mm Hg did not lower the rate of dementia or mild cognitive impairment [s1]. The imaging signal — less white-matter lesion growth with intensive control — is consistent with a vascular benefit, but it did not translate into fewer cognitive diagnoses over this follow-up, and the authors present it as a secondary observation [s1].
Several limits bound how far the result travels. The trial was open-label, so participants and treating clinicians knew their assigned target, even though outcome assessors did not [s1]. The imaging substudy was small relative to the whole trial, which widens the uncertainty around the white-matter finding. And the population was specific — adults with type 2 diabetes and elevated cardiovascular risk in China — so the cognitive result does not automatically generalise to people without diabetes or to other settings.
What to watch
Two questions follow naturally. The first is whether the slower accrual of white-matter lesions under intensive control eventually shows up as a cognitive difference with longer follow-up than 3.8 years, since dementia accumulates slowly. The second is whether blood-pressure strategy interacts with the glucose-lowering and lipid-lowering treatments these patients are also receiving. For now, the useful reading is narrow and clear: in type 2 diabetes, a tighter blood-pressure target bought a measurable change in the brain's small vessels but no measurable protection against dementia or mild cognitive impairment [s1].
This article describes trial results and is not medical advice. Decisions about blood-pressure targets belong with a person's own clinician.
Sources
- Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial — BMJ , November 12, 2026
- Blood Pressure Control Target in Diabetes (BPROAD) (NCT03808311) — ClinicalTrials.gov
More on
Does lowering blood pressure protect the ageing brain? The dementia result missed
A landmark trial pushed blood pressure hard and cut mild cognitive impairment — but its headline dementia result fell short of significance after the study stopped early. The pooled trial evidence is real, and modest.
A tighter blood-pressure target did not cut events in type 2 diabetes
OPTIMAL-DIABETES randomised 9,476 Brazilians with type 2 diabetes to a systolic target below 120 or below 140 mmHg. The tighter target cut pressure by about 14 mmHg but did not reduce major cardiovascular events.
Forgetting names and misplacing keys: when is memory slippage normal and when is it not?
Everyday lapses are a poor guide to trouble. The line that matters is whether memory loss is measurable beyond your age and whether it is starting to affect daily function.
Crossword-doers decline more slowly. That is not the same as crosswords working.
The link between puzzles and a sharper old age is real in the data and largely the wrong way round: the earliest changes of dementia quietly reduce the very activities that later look protective.